Biomarkers of sarcopenia in clinical trials—recommendations from the International Working Group on Sarcopenia

Sarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the r...

Full description

Bibliographic Details
Main Authors:	Cesari, Matteo, Fielding, Roger A., Pahor, Marco, Goodpaster, Bret, Hellerstein, Marc, Van Kan, Gabor A., Anker, Stefan D., Rutkove, Seward, Vrijbloed, J. Willem, Isaac, Maria, Rolland, Yves, M’Rini, Christine, Aubertin-Leheudre, Mylène, Cedarbaum, Jesse M., Zamboni, Mauro, Sieber, Cornell C., Laurent, Didier, Evans, William J., Roubenoff, Ronenn, Morley, John E., Vellas, Bruno
Format:	Online
Language:	English
Published:	Springer-Verlag 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424187/

id	pubmed-3424187
recordtype	oai_dc
spelling	pubmed-34241872012-08-27 Biomarkers of sarcopenia in clinical trials—recommendations from the International Working Group on Sarcopenia Cesari, Matteo Fielding, Roger A. Pahor, Marco Goodpaster, Bret Hellerstein, Marc Van Kan, Gabor A. Anker, Stefan D. Rutkove, Seward Vrijbloed, J. Willem Isaac, Maria Rolland, Yves M’Rini, Christine Aubertin-Leheudre, Mylène Cedarbaum, Jesse M. Zamboni, Mauro Sieber, Cornell C. Laurent, Didier Evans, William J. Roubenoff, Ronenn Morley, John E. Vellas, Bruno Original Article Sarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the results of a recent meeting of the International Working Group on Sarcopenia (a task force consisting of geriatricians and scientists from academia and industry) held on June 7–8, 2011 in Toulouse (France). The meeting was specifically focused at gaining knowledge on the currently available biomarkers (functional, biological, or imaging-related) that could be utilized in clinical trials of sarcopenia and considered the most reliable and promising to evaluate age-related modifications of skeletal muscle. Specific recommendations about the assessment of aging skeletal muscle in older people and the optimal methodological design of studies on sarcopenia were also discussed and finalized. Although the study of skeletal muscle decline is still in a very preliminary phase, the potential great benefits derived from a better understanding and treatment of this condition should encourage research on sarcopenia. However, the reasonable uncertainties (derived from exploring a novel field and the exponential acceleration of scientific progress) require the adoption of a cautious and comprehensive approach to the subject. Springer-Verlag 2012-08-03 2012-09 /pmc/articles/PMC3424187/ /pubmed/22865205 http://dx.doi.org/10.1007/s13539-012-0078-2 Text en © Springer-Verlag 2012
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Cesari, Matteo Fielding, Roger A. Pahor, Marco Goodpaster, Bret Hellerstein, Marc Van Kan, Gabor A. Anker, Stefan D. Rutkove, Seward Vrijbloed, J. Willem Isaac, Maria Rolland, Yves M’Rini, Christine Aubertin-Leheudre, Mylène Cedarbaum, Jesse M. Zamboni, Mauro Sieber, Cornell C. Laurent, Didier Evans, William J. Roubenoff, Ronenn Morley, John E. Vellas, Bruno
spellingShingle	Cesari, Matteo Fielding, Roger A. Pahor, Marco Goodpaster, Bret Hellerstein, Marc Van Kan, Gabor A. Anker, Stefan D. Rutkove, Seward Vrijbloed, J. Willem Isaac, Maria Rolland, Yves M’Rini, Christine Aubertin-Leheudre, Mylène Cedarbaum, Jesse M. Zamboni, Mauro Sieber, Cornell C. Laurent, Didier Evans, William J. Roubenoff, Ronenn Morley, John E. Vellas, Bruno Biomarkers of sarcopenia in clinical trials—recommendations from the International Working Group on Sarcopenia
author_facet	Cesari, Matteo Fielding, Roger A. Pahor, Marco Goodpaster, Bret Hellerstein, Marc Van Kan, Gabor A. Anker, Stefan D. Rutkove, Seward Vrijbloed, J. Willem Isaac, Maria Rolland, Yves M’Rini, Christine Aubertin-Leheudre, Mylène Cedarbaum, Jesse M. Zamboni, Mauro Sieber, Cornell C. Laurent, Didier Evans, William J. Roubenoff, Ronenn Morley, John E. Vellas, Bruno
author_sort	Cesari, Matteo
title	Biomarkers of sarcopenia in clinical trials—recommendations from the International Working Group on Sarcopenia
title_short	Biomarkers of sarcopenia in clinical trials—recommendations from the International Working Group on Sarcopenia
title_full	Biomarkers of sarcopenia in clinical trials—recommendations from the International Working Group on Sarcopenia
title_fullStr	Biomarkers of sarcopenia in clinical trials—recommendations from the International Working Group on Sarcopenia
title_full_unstemmed	Biomarkers of sarcopenia in clinical trials—recommendations from the International Working Group on Sarcopenia
title_sort	biomarkers of sarcopenia in clinical trials—recommendations from the international working group on sarcopenia
description	Sarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the results of a recent meeting of the International Working Group on Sarcopenia (a task force consisting of geriatricians and scientists from academia and industry) held on June 7–8, 2011 in Toulouse (France). The meeting was specifically focused at gaining knowledge on the currently available biomarkers (functional, biological, or imaging-related) that could be utilized in clinical trials of sarcopenia and considered the most reliable and promising to evaluate age-related modifications of skeletal muscle. Specific recommendations about the assessment of aging skeletal muscle in older people and the optimal methodological design of studies on sarcopenia were also discussed and finalized. Although the study of skeletal muscle decline is still in a very preliminary phase, the potential great benefits derived from a better understanding and treatment of this condition should encourage research on sarcopenia. However, the reasonable uncertainties (derived from exploring a novel field and the exponential acceleration of scientific progress) require the adoption of a cautious and comprehensive approach to the subject.
publisher	Springer-Verlag
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424187/
_version_	1611551032992595968

Biomarkers of sarcopenia in clinical trials—recommendations from the International Working Group on Sarcopenia

Similar Items